BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36989067)

  • 21. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
    Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
    Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
    Kim DY; Lee JH; Lee JH; Lee KH; Kim YK; Ahn JS; Kim HJ; Kim I; Yoon SS; Park S; Bae SH; Bang SM; Lee HG; Shin HJ; Lee JH; Min YH; Won JH; Mun YC; Oh D;
    Ann Hematol; 2010 Jan; 89(1):15-23. PubMed ID: 19543727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
    Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
    Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
    Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
    Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
    Reda G; Riva M; Fattizzo B; Cassin R; Giannarelli D; Pennisi M; Freyrie A; Cairoli R; Molteni A; Cortelezzi A
    Semin Hematol; 2018 Oct; 55(4):202-208. PubMed ID: 30502848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
    Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
    Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
    Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
    Oncotarget; 2016 Apr; 7(16):22103-15. PubMed ID: 26959885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
    Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
    Zhao YS; Guo J; Xu F; Wu D; Wu LY; Song LL; Xiao C; Li X; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):124-128. PubMed ID: 28279036
    [No Abstract]   [Full Text] [Related]  

  • 36. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
    Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H
    Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
    Cai L; Zhao X; Ai L; Wang H
    Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.